Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Change in Acquisitions & Divestments (2023)

Monte Rosa Therapeutics (GLUE) has 1 years of Change in Acquisitions & Divestments data on record, last reported at $45.6 million in Q1 2023.

  • For Q1 2023, Change in Acquisitions & Divestments changed N/A year-over-year to $45.6 million; the TTM value through Dec 2023 reached $45.6 million, changed N/A, while the annual FY2023 figure was $45.6 million, N/A changed from the prior year.
  • Change in Acquisitions & Divestments reached $45.6 million in Q1 2023 per GLUE's latest filing.
  • Across five years, Change in Acquisitions & Divestments topped out at $45.6 million in Q1 2023 and bottomed at $45.6 million in Q1 2023.